U.S. markets open in 39 minutes
  • S&P Futures

    4,404.00
    +9.25 (+0.21%)
     
  • Dow Futures

    34,750.00
    +60.00 (+0.17%)
     
  • Nasdaq Futures

    15,100.75
    +27.25 (+0.18%)
     
  • Russell 2000 Futures

    2,199.00
    +7.30 (+0.33%)
     
  • Crude Oil

    68.64
    +0.49 (+0.72%)
     
  • Gold

    1,813.80
    -0.70 (-0.04%)
     
  • Silver

    25.51
    +0.05 (+0.19%)
     
  • EUR/USD

    1.1840
    -0.0003 (-0.02%)
     
  • 10-Yr Bond

    1.1820
    -0.0020 (-0.17%)
     
  • Vix

    17.63
    -0.41 (-2.27%)
     
  • GBP/USD

    1.3912
    +0.0027 (+0.19%)
     
  • USD/JPY

    109.5860
    +0.1180 (+0.11%)
     
  • BTC-USD

    37,491.24
    -1,051.95 (-2.73%)
     
  • CMC Crypto 200

    927.62
    +0.85 (+0.09%)
     
  • FTSE 100

    7,117.48
    -6.38 (-0.09%)
     
  • Nikkei 225

    27,728.12
    +144.04 (+0.52%)
     

How Many Xenon Pharmaceuticals Inc. (NASDAQ:XENE) Shares Do Institutions Own?

  • Oops!
    Something went wrong.
    Please try again later.
·5 min read
In this article:
  • Oops!
    Something went wrong.
    Please try again later.

A look at the shareholders of Xenon Pharmaceuticals Inc. (NASDAQ:XENE) can tell us which group is most powerful. Institutions often own shares in more established companies, while it's not unusual to see insiders own a fair bit of smaller companies. Companies that have been privatized tend to have low insider ownership.

With a market capitalization of US$725m, Xenon Pharmaceuticals is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our data on the ownership groups (below), it seems that institutions own shares in the company. We can zoom in on the different ownership groups, to learn more about Xenon Pharmaceuticals.

View our latest analysis for Xenon Pharmaceuticals

ownership-breakdown
ownership-breakdown

What Does The Institutional Ownership Tell Us About Xenon Pharmaceuticals?

Institutional investors commonly compare their own returns to the returns of a commonly followed index. So they generally do consider buying larger companies that are included in the relevant benchmark index.

We can see that Xenon Pharmaceuticals does have institutional investors; and they hold a good portion of the company's stock. This can indicate that the company has a certain degree of credibility in the investment community. However, it is best to be wary of relying on the supposed validation that comes with institutional investors. They too, get it wrong sometimes. If multiple institutions change their view on a stock at the same time, you could see the share price drop fast. It's therefore worth looking at Xenon Pharmaceuticals' earnings history below. Of course, the future is what really matters.

earnings-and-revenue-growth
earnings-and-revenue-growth

Our data indicates that hedge funds own 21% of Xenon Pharmaceuticals. That catches my attention because hedge funds sometimes try to influence management, or bring about changes that will create near term value for shareholders. BVF Partners, L.P. is currently the largest shareholder, with 8.5% of shares outstanding. For context, the second largest shareholder holds about 6.8% of the shares outstanding, followed by an ownership of 6.4% by the third-largest shareholder. Furthermore, CEO Simon Pimstone is the owner of 0.5% of the company's shares.

A closer look at our ownership figures suggests that the top 11 shareholders have a combined ownership of 51% implying that no single shareholder has a majority.

Researching institutional ownership is a good way to gauge and filter a stock's expected performance. The same can be achieved by studying analyst sentiments. Quite a few analysts cover the stock, so you could look into forecast growth quite easily.

Insider Ownership Of Xenon Pharmaceuticals

The definition of company insiders can be subjective and does vary between jurisdictions. Our data reflects individual insiders, capturing board members at the very least. The company management answer to the board and the latter should represent the interests of shareholders. Notably, sometimes top-level managers are on the board themselves.

I generally consider insider ownership to be a good thing. However, on some occasions it makes it more difficult for other shareholders to hold the board accountable for decisions.

We can see that insiders own shares in Xenon Pharmaceuticals Inc.. It has a market capitalization of just US$725m, and insiders have US$25m worth of shares, in their own names. It is good to see some investment by insiders, but it might be worth checking if those insiders have been buying.

General Public Ownership

The general public, with a 22% stake in the company, will not easily be ignored. While this size of ownership may not be enough to sway a policy decision in their favour, they can still make a collective impact on company policies.

Private Equity Ownership

With a stake of 6.1%, private equity firms could influence the Xenon Pharmaceuticals board. Some might like this, because private equity are sometimes activists who hold management accountable. But other times, private equity is selling out, having taking the company public.

Public Company Ownership

Public companies currently own 3.4% of Xenon Pharmaceuticals stock. We can't be certain but it is quite possible this is a strategic stake. The businesses may be similar, or work together.

Next Steps:

I find it very interesting to look at who exactly owns a company. But to truly gain insight, we need to consider other information, too. For instance, we've identified 3 warning signs for Xenon Pharmaceuticals (1 is a bit concerning) that you should be aware of.

But ultimately it is the future, not the past, that will determine how well the owners of this business will do. Therefore we think it advisable to take a look at this free report showing whether analysts are predicting a brighter future.

NB: Figures in this article are calculated using data from the last twelve months, which refer to the 12-month period ending on the last date of the month the financial statement is dated. This may not be consistent with full year annual report figures.

This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.

Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team (at) simplywallst.com.